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ABSTRACT Bovine bone morphogenetic protein (bBMP)
induces differentiation of mesenchymal-type cells into cartilage
and bone. bBMP has an apparent Mr of 18,500 ± 500 and
represents <0.001% of the wet weight of bone tissue. A Mr
34,000 protein resembling osteonectin is separated by extrac-
tion with Triton X-100. A Mr 24,000 protein and about half of
a Mr 22,000 protein are disassociated from bBMP by precipi-
tation in 1.5 M guanidine hydrochloride. Aggregates of bBMP
and a Mr 14,000 protein are insoluble in aqueous media; the
bBMP becomes soluble when the Mr 14,000 protein is disasso-
ciated in 6 M urea and removed from the solution by ultrafil-
tration. Three separate molecular species with apparent Mrs
18,500, 17,500, and 17,000 are eluted at 0.10, 0.15, and 0.20
M phosphate ion concentrations, respectively, from a hy-
droxy-apatite column. The Mr 18,500 protein has the amino
acid composition of acidic polypeptide and includes four half-
cystine residues; the pI is 4.9-5.1. The Mr 22,000 component is
a chromoprotein resembling ferritin. The NH12-terminal amino
acid sequence of the Mr 17,500 protein simulates histone H2B.
The Mr 17,000 protein may possess calmodulin activity. Ag-
gregates of the Mr 18,500 and other proteins induce formation
of large deposits of bone; the Mr 18,500 protein alone is rapidly
absorbed and induces formation of small deposits. None of the
other proteins induces bone formation.
Under the influence of bone morphogenetic protein (BMP),
perivascular mesenchymal-type cells (pericytes) differenti-
ate into cartilage and woven bone. BMP is an acidic polypep-
tide (1, 2) embedded in a complex assortment of intra- and
extracellular protein aggregates derived from dentin (3),
bone (4, 5), and osteosarcoma tissues (6-9). We report here
on the purification of BMP by means of a combination of
differential precipitation, ultrafiltration, and hydroxyapatite
chromatography.
MATERIALS AND METHODS
Ten-kilogram batches of 1-year-old steer long bones were
obtained from an abattoir. After the epiphyseal ends were
cut away with a band saw, the diaphyses were mechanically
scraped clean of soft tissues and extensively washed in cold
water solution of 3 mM NaN3. The washed bone was frozen
in liquid N2, ground in a Wiley mill to a particle size of 1
mm3, defatted in chloroform/methanol (1:1), and again
washed in 10 liters of cold water (step 1). The bone particles
were demineralized in 0.6 M HCl at 4°C for 48 hr and again
extensively rewashed in NaN3 solution (step 2). The demin-
eralized washed bone particles were chemically extracted to
remove soluble noncollagenous protein (i.e., sialoproteins,
plasma proteins, y-carboxyglutamyl proteins, and phospho-
proteins), simultaneously converting the collagen to insolu-
ble bone matrix gelatin (step 3) by previously described pro-
cedures (10). Ten kilograms of whole wet bone produced
-'1.4 kg of freeze-dried insoluble bone matrix gelatin. The
BMP was extracted from the insoluble bone matrix gelatin in
an inorganic/organic solvent mixture of 0.5 M CaCl2 in 6 M
urea at 28°C for 24 hr containing 10 mM N-ethylmaleimide
(NEM) to protect BMP against endogenous degradative en-
zymes.
The undissolved matrix and other substances were re-
moved by filtration through cheesecloth. The supernatant
solution was decanted, dialyzed against 23 vol of deionized
water at 4°C, and allowed to stand overnight in the cold
while a precipitate formed. The precipitate was collected by
centrifugation (Sorvall RC-5B refrigerated superspeed) at
40,000 x g for 20 min, washed in cold deionized water, ly-
ophilized, and weighed (Table 1, step 4).
Sixty grams of the fraction obtained by step 4 (Table 1)
was redissolved in the original 0.5 M CaCl2/6 M urea solu-
tion and dialyzed against 11 vol of 0.25 M citrate buffer (pH
3.1) at 4°C. After 24 hr, a grayish-white precipitate was col-
lected by centrifugation at 40,000 x g for 1 hr. The precipi-
tate was extensively washed, defatted in chloroform/meth-
anol (1:1), and evaporated to dryness (step 5).
Twenty-two grams of the fraction obtained by step 5 (Ta-
ble 1) was redissolved in 4 M guanidine hydrochloride
(Gdn HCl) and diluted to 1.5 M Gdn HCl by dialysis at 28°C
for 12 hr or until formation of a precipitate. The 1.5 M
Gdn HCl-soluble fraction was dialyzed against water for 24
hr, until precipitation was complete. The water-insoluble
precipitate was centrifuged, extensively washed in cold wa-
ter, lyophilized, and weighed (step 6, Table 1). The 1.5 M
Gdn HCl-insoluble fraction was centrifuged at 50,000 x g for
1 hr, washed in cold water, lyophilized, and weighed (step
7). The protein fraction obtained by step 7 was redissolved in
0.5 M CaCl2/6 M urea and dialyzed against 0.2% Triton X-
100 in 0.10 M Tris HCl buffer solution (pH 7.2) containing 6
M urea for 24 hr at 28°C. The retentate was dialyzed exhaus-
tively against deionized water at 4°C until precipitation was
complete and then lyophilized (step 8). The Triton X-100-
soluble proteins were also lyophilized and weighed (step 9).
The precipitate from step 8 was redissolved in 6 M urea
and further purified by ultrafiltration (Amicon; pore size, Mr
10,000). When dialyzed against water, most of the retentate
did not precipitate and the soluble portion was Iyophilized
and collected for chromatographic fractionation.
Ultrafiltration. Two-liter batches of the CaCl2/urea-solu-
ble proteins in 0.01 M phosphate buffer (pH 7.0) in 6 M urea
were filtered through an H1P1O-8 hollow fiber cartridge
(Amicon; Mr 10,000, approximate cutoff). The retentate was
washed by passing an additional 6 liters of 6 M urea through
the hollow fibers and was dialyzed against deionized water at
Abbreviations: BMP, bone morphogenetic protein; bBMP, bovine
BMP; Gdn HCl, guanidine hydrochloride; IEF, isoelectric focusing.
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4TC. The precipitate and supernatant were lyophilized sepa-
rately.
NaDodSO4/Polyacrylamide Slab Gel Electrophoresis. The
above described protein fractions were solubilized by incu-
bation for 24 hr in 0.06 M Tris HCl (pH 6.8) containing 2 M
urea and 0.2% NaDodSO4. Five microliters (2.5 mg/ml) of
each sample was applied to a 12.6% gel with a 3% stacking
gel and was electrophoresed at 25 mA. The gels were stained
with 0.25% Coomassie brilliant blue R-250 in methanol/ace-
tic acid/H20 (5:1:5). The molecular weights were deter-
mined by using low molecular weight standards (Pharmacia),
with a range of Mr 94,000-14,400.
Preparative Gel Electrophoresis. Electrophoresis also was
performed with protein fractions applied to tube gels.
Stained and unstained gel cylinders were electrophoresed in
parallel and sliced to separate the individual bands. Selected
slices were applied to fresh disc gels with 3% agarose and re-
electrophoresed to verify the homogeneity of the protein
samples. The individual protein constituents were eluted
with 6 M urea, dialyzed against water, and lyophilized.
Preparative Flatbed Electrofocusing in a Granulated Gel.
Two-hundred-milligram samples were dissolved in 95 ml of 4
M urea and added to 5 ml of ampholyte (Biolyte, Bio-Rad).
After electrofocusing, each band was cut out of the gel sepa-
rately with a spatula. Each of the gel samples was trans-
ferred to columns and eluted with 5 ml of 6 M urea in 0.5 M
CaCl2 for a solvent. The eluate was collected in tubes and the
pH was determined for each sample.
Hydroxyapatite Chromatography. Hydroxyapatite col-
umns of Bio-Gel HTP (Bio-Rad) were prepared by adding 15
g of hydroxyapatite to 100 ml of 0.05 M phosphate buffer (pH
7.3) containing 6 M urea. After 10 min the solvent was de-
canted and the hydroxyapatite was resuspended in 100 ml to
give a settled bed height of 9 cm (volume, -55 ml). The col-
umn was equilibrated with 100 ml of starting buffer, using a
gravity flow rate of 0.6 ml/min. Samples'of 100 mg of the
preparation obtained by step 8 were dissolved in 6 M urea,
applied to the column, and separated into fractions.
Hydrophobic Column HPLC. Further purification of the
protein fraction isolated by hydroxyapatite chromatography
was accomplished by HPLC using a hydrophobic column
(Ultrapore, reverse-phase Spherogel column, Beckman).
One-milligram samples were dissolved in 0.1% phosphoric
acid/0.1 M sodium perchlorate/5% trifluoracetic acid. The
solution was applied to the column and eluted with a gradient
of (i) 0.1% H3PO4/0.1 M NaClO4 in water and (ii) 0.1%
H3PO4/0.1 M NaClO4 in a mixture of acetonitrile/H20
(70:30), in 100 min with a flow rate of 1.0 ml/min.
Amino Acid Analysis. The individual proteins isolated by
preparative gel electrophoresis were hydrolyzed at 110'C for
24 hr in 6 M HCl in evacuated sealed tubes. Analysis for
tryptophan was performed after hydrolysis at 110'C for 24 hr
in 2.5 M KOH/cystine, following performic acid oxidation;
y-carboxyglutamic acid was determined by P. A. Price (11).
Amino acid analysis was performed on an amino acid analyz-
er (Beckman 119 C) equipped with a Spectra Physics 4000
data reduction system.
Amino Acid Sequences. The Mr 18,500 and Mr 17,500 com-
ponents, further purified by hydrophobic column chroma-
tography, were analyzed in the gas/liquid phase protein se-
quenator (12).
Bioassay. BMP activity was determined by implantation of
isolated protein fractions and individual proteins in the hind-
quarter muscles of Swiss-Webster strain mice and skull tre-
phine defects in monkeys, dogs, and rats.
RESULTS
Table 1 summarizes nine steps in the chemical extractions of
BMP and associated proteins by differential precipitation
and lists the yields of new bone from implants of the various
protein fractions.
Changes in Solubility Produced by Ultrafiltration. A pro-
tein and protein aggregate with high BMP activity, obtained
by step 8, are soluble only in 6-8 M urea or 4M Gdn HCl and
insoluble in water. After large quantities of the Mr 14,000
component (but not all of the Mr 14,000 protein and some
lower molecular weight proteins) were removed by ultrafil-
tration of a 6 M urea solution, the Mr 18,500, 17,500, and
17,000 proteins became soluble in. water.
Triton X-100-Soluble Proteins. The Triton X-100-soluble,
Mr 34,000 protein (isolated by step 9) was the single most
abundant noncollagenous protein of the group lacking BMP
activity. Specimens sent to J. D. Termine (5) for analytical
Table 1. Yield of BMP from bovine bone
Mr x 10-3 of major Induced bone formationt
electrophoretic Incidence, Yield,
Step Fraction* Weight, g components t n mm3/mg
1 Wet bone, fresh, pulverized 10.0- 0 10 0
2 Dry, fat-free demineralized§ 3.0t 0 30 0
3 Bone matrix gelatin 1.4i: 48 40 0.5
4 0.5 M CaC12/6.0 M urea soluble, 0.25
M urea insoluble 60.0 78 50 1.5
5 0.5 M CaC12/6.0 M ureas 22.0 18, 68, 45, 34, 17-
18, 14, 12, 5 80 50 20
6 4 M Gdn HCl soluble, 1.5 M Gdn HCl
soluble, water insoluble 7.23 45, 34, 24, 22, 18-
17, 14, 12 88 30 2.5
7 1.5 M Gdn-HCl insoluble 12.0 34, 22, 17 8 20 0.5
8 0.5 M CaCl2/6.0 M urea solublell 1.5 22, 12-18, 14, 12, 5 96 60 8.0
9 Dialyze supernatant against water and
lyophilize 5.3 65, 45, 34, 22, 12 0 20 0
*BMP activity = 0.001% of wet bone.
tImplants in rump of athymic, cortisone-immunosuppressed, or untreated mice. n = number of implants.
tWeight in kg.
§BMP activity = 0.003% of demineralized lyophilized fat-free bone matrix.$Dialyze against 0.25 M citrate buffer (pH 3.1). Wash precipitate in water, centrifuge, redefat in chloroform/methanol (1:1). Evaporate to
dryness.
IDialyze against 0.2% Triton X-100/0.10 M Tris HCl in 6 M urea (pH 7.2) for 24 hr. Then dialyze against deionized water until precipitation is
complete.
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FIG. 1. Staining pattern of proteins fractionated by IEF. Esti-
mates of the pl are indicated by the scale across the top. The results
of bioassay of each fraction are shown by the symbols across the
bottom. The two fractions with pl values ranging from 4.93 to 5.18
induced bone formation in the mouse's thigh muscle pouch; all of
the fractions with pl values above 5.18 or below 4.93 induced forma-
tion of fibrous tissue only.
immunoprecipitation were found to crossreact with a Mr
32,000 protein named osteonectin.
Flatbed Isoelectric Focusing (IEF). Fig. 1 illustrates the re-
sults of fractionation of proteins obtained by step 8 (Table 1)
by IEF. Two fractions with pl values of 4.9 and 5.3, collect-
ed by elution of the gel slices with 0.5 M CaCI2/6 M urea,
contained an aggregate of three proteins-i.e., Mr 22,000,
18,500 ± 500, and 14,000 components-and had BMP activi-
ty. Seven other fractions in the pl range of 4.3-7.5 had no Mr
18,500 component and no BMP activity.
Preparative Gel Electrophoresis. Slices of stained and un-
stained tube gels were extracted with 6 M urea to isolate the
individual proteins and re-electrophoresed on slab gels. The
Mr 24,000, 17,500, 17,000, and 14,000 components migrated
the same distances as in the unsliced gels. The Mr 18,500
component also migrated the same distance but, in addition,
produced three lower molecular weight components, Mr
14,000, 6,000, and 4,000.
Hydroxyapatite Chromatography. Fig. 2 illustrates the ab-
sorbance patterns of various protein fractions eluted by a
gradient of 0.05-0.3 M phosphate buffer at pH 7.3. Three
proteins in the range of Mr 17,000-18,000 were separated
from the Mr 22,000, 14,000, and other low molecular weight
proteins by means of hydroxyapatite chromatography. A M,
22,000 protein and other proteins lacking BMP activity were
yellowish brown in color and were recovered in solutions of
phosphate ions ranging from 0.05 to 0.10 M in concentration.
Fractions containing components in the range of Mr 17,000-
18,000 (with traces of Mr 14,000 and Mr 22,000 proteins)
were generally eluted at concentrations of phosphate buffer
of 0.18-0.2 M. By rechromatographing this fraction, it was
possible to purify each of the three with variable degrees of
contamination with Mr 14,000 and other low molecular
weight proteins (Fig. 2 Center and Right). The protein with
BMP activity was white in color and fluffy in texture and had
an apparent Mr of 18,500 ± 500; the Mr 17,500, 17,000, and
lower molecular weight proteins did not induce bone forma-
tion.
Amino Acid Analysis. The Mr 18,500 ± 500 BMP had the
composition of an acidic polypeptide and may include one
residue of hydroxyproline and possibly y-carboxyglutamic
acid (Table 2). Three -carboxyglutamic acid (Gla) residues
were found in the Mr 14,000 protein, whereas none was de-
tected in the Mr 22,000 or 34,000 proteins (13).
Hydrophobic HPLC. A protein with a Mr of '17,500 was
isolated by hydrophobic gel HPLC. Isolated from the Mr
18,500 component, the Mr 17,500 protein failed to induce
bone formation.
Amino Acid Sequence. Insofar as the NH2-terminal amino
acid was unblocked, the Mr 17,500 component was selected
for amino acid sequence analysis. The first 25 amino acids
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FIG. 2 (Left) Absorbance curve obtained by hydroxyapatite chromatography of 1.5 M Gdn-HCI-soluble, water-insoluble proteins (obtained
in step 6, Table 1). The proteins with BMP activity were eluted at phosphate ion concentrations (shown across the top) ranging from 0.18 to 0.20
or 0.25 M (pH 7.3). (Center) Electrophoretic patterns of protein fractions obtained by hydroxyapatite chromatography. Protein fractions with
apparent Mrs of 17,000, 17,500, and 18,000 were eluted at phosphate concentrations of 0.18, 0.20, and 0.25 M, respectively. Only samples
containing the Mr 18,500 component (including the starting material and the fraction eluted at 0.25 M phosphate) induced bone formation.
(Right) Electrophoretic patterns of a purified Mr 18,500 protein after removal of most of the Mr 14,000 protein by ultrafiltration. The Mr 18,500
protein was further purified by hydroxyapatite chromatography in 6 M urea and eluted at 0.22 M phosphate ion concentration. A small amount
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Table 2. Amino acid analysis of Mr 18,500 ± 500 BMP
mol Residues/ Assumed
Residue nmol % 18,500* residues Weight
Asxt 23.7 10.5 17.6 18 2,071
Thr 9.20 4.1 6.89 7 708
Serf 22.5 10.0 16.8 17 1,480
Glxt 33.6 14.9 25.0 25 3,228
Pro 13.5 6.0 10.1 10 971
Gly 20.7 9.2 15.5 16 913
Ala 14.3 6.3 10.6 11 782
Val§ 12.5 5.5 9.2 9 892
Met 2.53 1.1 1.85 2 262
Ile§ 5.65 2.5 4.20 4 453
Leu 15.3 6.8 11.4 11 1,245
Tyr 8.39 3.7 6.22 6 979
Phe 8.62 3.8 6.38 6 883
Lys 8.62 3.8 6.38 6 769
His 4.29 1.9 3.19 3 411
Arg 16.1 7.1 11.9 12 1,874
Cys$ 6.32 2.8 4.70 5 515
Trp ND
Total 100.0 168 18,43611
ND, not determined.
*Calculations on these samples assume Mr = 18,500.
tAsx = Asp and Asn; Glx = Glu and Gln.
tSer values corrected by 10o due to destruction during acid hydrol-
ysis.
§Val and Ile values may be low because only 24 hr of hydrolysis was
used.$Half-cystine determined as cysteic acid after performic acid oxida-
tion.
'Plus possibly some y-carboxyglutamic acid residues and one hy-
droxyproline residue.
The Mr 18,000 ± 500 putative BMP had a blocked NH2-ter-
minus.
Mercaptoethanol Reduction. No significant measurable dif-
ferences in the electrophoretic mobility of the three compo-
nents with Mrs in the range of 17,000-18,000 were noted be-
fore and after mercaptoethanol reduction. Nevertheless,
BMP activity was destroyed by mercaptoethanol reduction.
Bioassay. When the Mr 18,500 ± 500 component was pres-
ent, implants of protein fractions isolated by hydroxyapatite
chromatography induced bone formation in the mouse hind-
quarter muscles (Fig. 3 Left and Right) and produced regen-
eration in trephine defects in rat and dog skulls (Fig. 4). Im-
FIG. 3 (Left) Roentgenogram of a deposit of bone (arrow) 3
weeks after implantation of 5 mg of a Mr 18,500 ± 500 bovine BMP
(bBMP) (isolated by hydroxyapatite chromatography) in a mouse
thigh muscle. The contralateral thigh (control) was implanted with 5
mg of bovine albumin. (Right) Photomicrograph of a cross section of
the deposit shown on the Left. N, new bone; R, bone marrow.
(x 100; hematoxylin/eosin and azure II stains.)
FIG. 4. Roentgenogram of dog skull showing two trephine de-
fects, 8 weeks after the operation. The left defect, implanted with 50
mg of bBMP prepared by step 8 (Table 1), was completely repaired
by new bone. The right defect, implanted with 50 mg of bovine albu-
min as a control, failed to heal.
plants of 10 mg or more ofMr 14,000, 17,500, 17,000, 22,000,
or 34,000 proteins, alone or in various combinations, failed
to induce bone formation. Association of the Mr 18,500 pro-
tein with the Mr 14,000 protein decreased solubility in vitro,
increased resorption time in vivo, and improved both the in-
cidence and yield of new bone from implants of as little as 1
mg. Implants of combinations of Mr 18,500 protein with Mr
34,000 protein or Mr 34,000 protein and Mr 17,500 protein did
not improve and may even have suppressed the bone forma-
tion. Implants of seven parts of Mr 22,000 protein, two parts
of Mr 18,500 ± 500 protein, and one part ofMr 14,000 protein
weighing 3 mg induced formation ofbone consistently and in
quantities exceeding the space the mouse thigh could contain
(Fig. 5).
DISCUSSION
Due to the densely packed bone matrix structure, the rela-
tively small quantity compared with other noncollagenous
proteins, and an inclination to form hydrophobic aggregates,
BMP is difficult to isolate and purify. The first evidence that
isolation was possible came when BMP was released from
bone matrix gelatin by digestion with gelatinase, separated
from the digest by coprecipitation with calcium phosphate
(14), and proven to be a noncollagenous protein in nature.
However, it was not until it was quantitatively extracted
from bone matrix by means of a CaCl2/urea solvent mixture
and the hydrophobic low molecular weight proteins were
solubilized and disassociated from each other in 4 M
Gdn HCl that BMP was isolated in significant quantities for
detailed analysis (4, 5, 15). The combination of procedures
reported here demonstrate: (i) three separate proteins with
Mrs of 18,500, 17,500, and 17,000; (ii) three proteins of high-
er Mr (34,000, 24,000, and 22,000); and (iii) one or more pro-
teins of lower Mr (14,000). One procedural improvement
separates most of a Mr 34,000 protein, osteonectin (16) (rep-
resenting about half of the total noncollagenous proteins), by
virtue of its solubility in 0.2% Triton X-100; BMP is insoluble
FIG. 5. Roentgenogram of large deposits of bone (arrows) over-
flowing the limbs of the mouse thigh in response to an implant of two
parts of 18,500 protein, seven parts of Mr 22,000 protein, and one
part of M, 14,000 protein weighing a total of only 3 mg, 21 days after
the operation.
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in Triton X-100. Another improvement is in the use of ultra-
filtration to separate the Mr 14,000 protein and other low mo-
lecular weight proteins that have a high affinity for BMP; by
removal of large quantities of Mr 14,000 protein, BMP be-
comes soluble in water. Another improvement is obtained by
the use of hydroxyapatite chromatography, which separates
a Mr 18,500 BMP from a Mr 17,500 protein resembling his-
tone H2B (identified from its NH2-terminal amino acid se-
quence), from a Mr 17,000 protein (which may have calmo-
dulin activity), and from a Mr 22,000 chromoprotein (possi-
bly ferritin identified by immunoprecipitation from horse
antiferritin). With the exception of the Mr 22,000 compo-
nent, these proteins are generally contaminated with small
quantities of Mr 14,000 protein or traces of Mr 6,000 and Mr
4,000 constituents. The Mr 22,000 protein is found in the un-
bound fraction and is relatively easy to purify. In contrast,
the separation of the proteins of Mrs 18,500, 17,500, and
17,000 from each other and from other lower molecular
weight proteins is arduous and is a painstaking process.
Preparative IEF indicates the pI of the Mr 18,500 molecule
to be in the range of 4.9-5.1 but does not produce clean sepa-
ration of bBMP from the Mr 17,500, 17,000, or 14,000 pro-
teins. The Mr 17,500 histone H2B-like protein has no BMP
activity. We have implanted 2 mg of histone H2B, prepared
from Dunn osteosarcoma (6), a tissue with higher BMP ac-
tivity than bone itself, and observed no BMP activity. Pres-
ent evidence is against any protein other than the Mr 18,500
protein as inducing bone formation. Osteoinductive activity
is extinguished from bone matrix by mercaptoethanol reduc-
tion (17). This observation suggests that the BMP is a disul-
fide-bonded molecule. Special investigations are required to
determine the number of disulfide bonds and the position
with respect to one or the other end of the molecule.
The affinity and capacity of BMP for calcium binding has
not yet been measured but preliminary experiments indicate
each to be on the order of serum proteins. However, Ca2+
alterations in the solubility of low molecular weight proteins
associated with BMP are important and could influence the
delivery of BMP to target cells. Upon further characteriza-
tion, the Mr 14,000 protein is designated as matrix Gla pro-
tein (MGP); through formation of a MGP-Ca2+-BMP aggre-
gate, MGP could regulate local transfer ofBMP from matrix
to mesenchyme (13). BMP also adsorbs to bone mineral and
coprecipitates with calcium phosphate, but it is completely
recovered by extraction of the mineral with 4 M Gdn HCl. A
summary of physicochemical properties of BMP prepared
from experiments previously and presently performed by
our research group follows: (i) acidic polypeptide; (ii) appar-
ent Mr = 18,000 ± 500 and pI = 5.0 + 0.2; (iii) binds to
hydroxyapatite; (iv) no carbohydrate detected; (v) soluble in
neutral salt solution at pH 7.2; (vi) degraded by acid alcohol
solutions; alkali sensitive; (vii) insolubilized by forming ag-
gregates with Mr 14,000 proteins; (viii) may contain one resi-
due of hydroxyproline; (ix) insoluble in chloroform/
methanol, absolute alcohol, and acetone; (x) BMP Mr 14,000
complex: insoluble in Triton X-100 (non-ionic detergent); in-
soluble in 0.6 M HCl; soluble in 6 M urea or 4 M Gdn HCl;
soluble in 0.1% NaDodSO4; soluble in 0.02% M HCl; par-
tially soluble in ethylene glycol; (xi) nuclease (RNase and
DNase) resistant; (xii) trypsin and chymotrypsin labile; (xiii)
resistant to: chondroitinases A, B, and C, amylase, neur-
aminidase, hyaluronidase, alkaline phosphatase, acid
phosphatase, chymopapain, collagenase, tyrosinase, and
thermolysin.
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